Specific Use-result Surveillance of Spiriva Respimat in Asthmatics

Boehringer Ingelheim

Status: Completed

Conditions: Asthma

Treatments: Drug: Spiriva

Study type: Observational

Funder types: Industry

Identifiers

NCT02489981

205.525

Details and patient eligibility

About

The safety of Spiriva® 2.5 µg Respimat® 60 puffs (hereinafter referred to as Spiriva® Respimat®) in patients with severe persistent asthma under the real-world use was not confirmed in clinical trials.

Enrollment: 359 patients

Sex: All

Ages: 15+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with severe persistent bronchial asthma
• Patient aged >= 15 years
• Patients who are naive to Spiriva Respimat and receive Spiriva Respimat for the first time for treatment of bronchial asthma on top of at least ICS (Inhaled corticosteroids) treatment.

Exclusion criteria

• Patients who have a contraindication to Spiriva Respimat defined in the package insert for Spiriva Respimat
• Patients who have been enrolled this study before.

Trial design

359 participants in 1 patient group

Spiriva

Description:

Patients with severe persistent asthma

Treatment:

Drug: Spiriva